Epigenetic Abnormalities in Chondrosarcoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24054539 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Michał Bereza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Hauptthemen laut MEDLINE: MicroRNAs, Chondrosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center.
Abstract (Originalsprache)
In recent years, our understanding of the epigenetic mechanisms involved in tumor pathology has improved greatly. DNA and histone modifications, such as methylation, demethylation, acetylation, and deacetylation, can lead to the up-regulation of oncogenic genes, as well as the suppression of tumor suppressor genes. Gene expression can also be modified on a post-transcriptional level by microRNAs that contribute to carcinogenesis. The role of these modifications has been already described in many tumors, e.g., colorectal, breast, and prostate cancers. These mechanisms have also begun to be investigated in less common tumors, such as sarcomas. Chondrosarcoma (CS) is a rare type of tumor that belongs to sarcomas and is the second most common malignant bone tumor after osteosarcoma. Due to unknown pathogenesis and resistance to chemo- and radiotherapies of these tumors, there is a need to develop new potential therapies against CS. In this review, we summarize current knowledge on the influence of epigenetic alterations in the pathogenesis of CS by discussing potential candidates for future therapies. We also emphasize ongoing clinical trials that use drugs targeting epigenetic modifications in CS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.
- Department of Experimental Pharmacology, Mossakowski Medical Research Centre Polish Academy of Sciences, 02-106 Warsaw, Poland.
ORCID-Profile: Agnieszka E Zając, Monika Dudzisz-Śledź, Piotr Rutkowski, Anna M Czarnecka
Förderung
- National Science Center
Zitieren
APA
Bereza, M., Dembiński, M., Zając, A. E., Piątkowski, J., Dudzisz-Śledź, M., Rutkowski, P., & Czarnecka, A. M. (2023). Epigenetic Abnormalities in Chondrosarcoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054539
Vancouver
Bereza M, Dembiński M, Zając AE, Piątkowski J, Dudzisz-Śledź M, Rutkowski P, et al. Epigenetic Abnormalities in Chondrosarcoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054539
BibTeX
@article{Bereza2023,
author = {Bereza, Michał and Dembiński, Mateusz and Zając, Agnieszka E and Piątkowski, Jakub and Dudzisz-Śledź, Monika and Rutkowski, Piotr and Czarnecka, Anna M},
title = {Epigenetic Abnormalities in Chondrosarcoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24054539}
}
EUVIMED